Peptide Library

FDA-approved

Immune & defense

Enfuvirtide

Evidence

FDA approved

Class

HIV fusion inhibitor peptide

/

Enfuvirtide

KEY TAKEAWAY

Enfuvirtide is a 36-amino-acid synthetic peptide that mimics part of the HIV envelope protein gp41. It is sold as Fuzeon. The FDA approved enfuvirtide (Fuzeon) in 2003 as the first HIV fusion inhibitor, for people who had already tried other HIV drugs.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

HIV fusion inhibitor peptide

Approved for

HIV-1 infection that has resisted other treatments

Key fact

The FDA approved enfuvirtide (Fuzeon) in 2003 as the first HIV fusion inhibitor, for people who had already tried other HIV drugs.

Route

Twice-daily subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Enfuvirtide is a 36-amino-acid synthetic peptide that mimics part of the HIV envelope protein gp41. It is sold as Fuzeon.

How it works

How it works

It binds gp41 and stops the virus from fusing with and entering human immune cells.

Regulatory status

Regulatory status

The FDA approved enfuvirtide (Fuzeon) in 2003 as the first HIV fusion inhibitor, for people who had already tried other HIV drugs.

What it is used for

What it is used for

HIV-1 infection that has resisted other treatments.

Side effects and risks

Side effects and risks

Injection-site reactions are very common. Bacterial pneumonia and allergic reactions are less common but serious.

Citations

Citations

U.S. FDA prescribing information for Enfuvirtide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo